AHRQ RFA-HS-10-004

Recovery Act 2009 Limited Competition: Innovative Adaptation and Dissemination of AHRQ Comparative Effectiveness Research Products (iADAPT) (R18)

Application Due Date(s):  December 16, 2009

This AHRQ Funding Opportunity Announcement (FOA), supported by funds provided to AHRQ under the American Recovery & Reinvestment Act of 2009 (“Recovery Act” or “ARRA”), Public Law 111-5, invites Research Demonstration and Dissemination grant (R18) applications from organizations to extend the reach and impact of Comparative Effectiveness Research (CER) Reviews and associated products, particularly Comparative Effectiveness Research Summary Guides (CERSGs) prepared by the John M. Eisenberg Center for Clinical Decisions and Communications Science part of the AHRQ Effective Health Care Program.(See DOC1 and DOC2 for information about CERSGs and CER Reviews respectively.)  Summary guides are intended to help bridge the gap between research and practice by translating and disseminating findings on the comparative effectiveness of clinical interventions for three broad audiences – patients/consumers, clinicians, and policymakers.  Applicants are invited to propose innovative customizations or adaptations (as defined in this FOA under Part II Section I.1 Research Objectives subsection) to the content presentation and/or delivery mechanism(s) of one or more Comparative Effectiveness Research Review Products, such as Comparative Effectiveness Reviews, Comparative Effectiveness Review Executive Summaries, or Comparative Effectiveness Research Summary Guides (CERSGs) where additional adaptations or customizations are aimed at increasing their use, implementation, and impact among difficult-to-reach populations, including the elderly, those with limited English proficiency, limited education or insurance coverage, minority or immigrant status, health literacy problems, or other underserved populations who may have limited contact with the health care system or health information.  Adaptations should aim to increase the impact and effective use of one or more CER Review Products by developing, implementing, and evaluating customizations that target important audiences, stakeholders, systems, or settings; these customizations may be in the adaptation of the original CER Review or Executive Summary contents to a specialized clinical audience of potential users (such as Formulary or Pharmaceutical and Therapeutics Committees, health care systems with electronic platforms such as electronic medical records (EMRs) that could support clinical decision support) or adaptation of CERSGs (supplemented as deemed necessary with pertinent information found solely in the CER Reviews) to underserved populations of patients/consumers whose interface with medical or Internet sources of information is limited and who may instead use health care information and advice provided through traditional means, such as neighborhood-, community-, or faith-based groups.  For CER Review Products or CERSGs, adaptations may address the presentation of the content and/or the mechanisms by which the contents are delivered or used. 

The total costs for any grant awarded under this FOA will not exceed $1.5 million for the entire project period, which may not exceed 3 years.  An application with a budget that exceeds $1.0 million in total costs in any one year, $1.5 million over 3 years, or that exceeds 3 years in duration will not be reviewed.  Funding beyond the first year will be contingent upon a review and acceptance by Agency staff of the annual progress report.

The Research Plan component may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts.

RFA:  http://grants.nih.gov/grants/guide/rfa-files/RFA-HS-10-004.html